In Interim Results from Phase 3 Study, Merck's Investigational Ebola Vaccine Efficacious; Study is Continuing

In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing

Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year

KENILWORTH, N.J., July 31, 2015 -- Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea.

Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet.

The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination.

Anexo:

• Merck News Release 07 31 15- In Interim Results from Phase 3 Study, Merck's Investigational Ebola VaccineEfficacious Study is Continuing

Posted in: